Patents by Inventor Mark Cornell Manning

Mark Cornell Manning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE ANTI-OSMR ANTIBODY FORMULATION
    Publication number: 20250114449
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: May 23, 2024
    Publication date: April 10, 2025
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
    Publication number: 20250084156
    Abstract: The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.
    Type: Application
    Filed: July 15, 2024
    Publication date: March 13, 2025
    Inventors: Henrik Rajesh Kumar PARSHAD, Anne Sofie MARKUSSEN, Mark Cornell MANNING, Derrick Spencer KATAYAMA, Magdalena GAUDEN, John SMITH
  • PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOF
    Publication number: 20240425567
    Abstract: The present disclosure is directed to pharmaceutical formulations comprising antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S). Other embodiments of the disclosure include the use of pharmaceutical formulations for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or prophylactically beneficial.
    Type: Application
    Filed: October 7, 2022
    Publication date: December 26, 2024
    Inventors: Rebecca Dabora, Gayathri Ratnaswamy, Sheryl Martin-Moe, Mark Cornell Manning, Ryan Holcolm
  • COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
    Publication number: 20240025979
    Abstract: The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.
    Type: Application
    Filed: June 26, 2023
    Publication date: January 25, 2024
    Inventors: Josefine NIELSEN SØDERBERG, Pekka Kallunki, Louise Buur, Frank Larsen, Henrik Rajesh Kumar Parshad, Anne Sofie Markussen, Mark Cornell Manning, Derrick Spencer Katayama, Magdalena Gauden, John Smith
  • C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
    Patent number: 11534482
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: December 27, 2022
    Assignee: VIROPHARMA BIOLOGICS LLC
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
    Patent number: 11364288
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: June 21, 2022
    Assignee: VIROPHARMA BIOLOGICS LLC
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • Stable Anti-OSMR Antibody Formulation
    Publication number: 20220062414
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: September 8, 2021
    Publication date: March 3, 2022
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • Stable anti-OSMR antibody formulation
    Patent number: 11141479
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: October 12, 2021
    Assignee: KINIKSA PHARMACEUTICALS, LTD.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • METHODS AND COMPOSITIONS COMPRISING SURFACTANT PROTEIN D (SP-D)
    Publication number: 20210121536
    Abstract: Some embodiments provided herein relate to methods and pharmaceutical compositions comprising recombinant human surfactant protein D or active fragments thereof. Some such embodiments include solutions or suspensions, and lyophilized solid forms of recombinant human surfactant protein D or active fragments thereof.
    Type: Application
    Filed: March 27, 2019
    Publication date: April 29, 2021
    Inventors: Jan Susan Rosenbaum, Mark Cornell Manning, Derrick S. Katayama, Giovanni M. Pauletti, Shawn Grant, Ryan Holcomb
  • SYSTEMS AND METHODS FOR CHARACTERIZING SURFACTANT PROTEIN D (SP-D) OLIGOMERS
    Publication number: 20210010988
    Abstract: Some embodiments of the methods and compositions provided herein include identifying and/or quantifying oligomeric species of surfactant protein-D (SP-D). Some embodiments include performing an asymmetric flow field-flow fractionation with multi-angle laser light scattering (AF4-MALLS) analysis on the SP-D.
    Type: Application
    Filed: March 27, 2019
    Publication date: January 14, 2021
    Inventors: Jan Susan Rosenbaum, Mark Cornell Manning, Ryan R. Manning
  • C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY
    Publication number: 20200261556
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Application
    Filed: October 2, 2019
    Publication date: August 20, 2020
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • Stable Anti-OSMR Antibody Formulation
    Publication number: 20200061188
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: August 26, 2019
    Publication date: February 27, 2020
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • Stable anti-OSMR antibody formulation
    Patent number: 10493149
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: December 3, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • Stable anti-OSMR antibody formulation
    Patent number: 10391170
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: August 27, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY
    Publication number: 20190160157
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Application
    Filed: August 2, 2018
    Publication date: May 30, 2019
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY
    Publication number: 20190160158
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficienty are disclosed.
    Type: Application
    Filed: September 5, 2018
    Publication date: May 30, 2019
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • STABLE ANTI-OSMR ANTIBODY FORMULATION
    Publication number: 20190054169
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: November 2, 2018
    Publication date: February 21, 2019
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency
    Patent number: 10201595
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: February 12, 2019
    Assignee: Shire ViroPharma Incorporated
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • Antibody formulations and uses thereof
    Patent number: 10195281
    Abstract: The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: February 5, 2019
    Assignee: Tracon Pharmaceuticals, Inc.
    Inventors: Suzanne Benedict, Mark Cornell Manning, Brian M. Murphy, Sharon Real, Charles Theuer
  • STABLE ANTI-OSMR ANTIBODY FORMULATION
    Publication number: 20180333489
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: April 11, 2018
    Publication date: November 22, 2018
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M. Levesque, Ryan Erik Holcomb